Table 2.

Seroconversion rates of antibodies to live SARS-CoV-2, IgG and IgM.

	Seroconversion rates	Antibody levels
Cohort 1
Neutralizing antibodies to live SARS-CoV-2
Day 56	53(77.9%; 67.8-88.1)	5.87 (4.6-7.7)
Day 210	9(13.2%; 5.0-21.5)	2.28 (2.1-2.5)
IgG (AU/ml)
Day 0	0(0.0%)	0.6 (0.4-0.8)
Day 28	19(27.9%; 17.0-38.9)	9.0 (5.9-12.0)
Day 56	66(97.1%; 92.9-101.2)	60.4 (47.3-73.5)
Day 210	17(25.0%; 14.4-35.6)	8.4 (5.8-11.1)
IgM (AU/ml)
Day 0	0(0.0%)	0.4 (0.3-0.4)
Day 28	7(10.3%; 2.9-17.7)	4.9 (2.9-6.9)
Day 56	9(13.3%; 5.0-21.5)	5.1 (3.2-6.9)
Day 210	0(0.0%)	0.2 (0.1-0.2)
Cohort 2
Neutralizing antibodies to live SARS-CoV-2
Day 56	54(78.3%; 68.3-88.2)	5.2 (4.1-6.5)
IgG (AU/ml)
Day 56	66(95.7%; 90.7-100.6)	55.8 (46.4-65.2)
Day 210	14(20.3%; 10.6-30.0)	6.8 (4.8-8.8)
IgM (AU/ml)
Day 56	2(2.9%; -1.2-7.0)	1.9 (1.3-2.6)
Day 210	0(0.0%)	0.3 (0.1-0.5)